4 recruiting, 2 completed, 1 active not recruiting, 1 terminated. 5 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Recruiting 2, Active not recruiting 1, Completed 1, Terminated 1 |
| Phase 1 | 1 | Recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow Myeloid Sarcoma: new trials by email Literature Review of Myeloid Sarcoma trials Research Report on Myeloid Sarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| VAM in Secondary AML, AML With Extramedullary Involvement, and Myeloid Sarcoma VAM_GROUP - Acute Myeloid Leukemia, Myeloid Sarcoma | Phase 2 | Recruiting | Ruijin Hospital | 48 | 2025-06-20 | 2025-07-09 |
| Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary Involvement Acute Myeloid Leukemia, Myelodysplastic Neoplasm | Recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 50 | 2024-01-20 | 2024-07-22 | |
| A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML Ziftomenib, Venetoclax, Azacitidine - Acute Myeloid Leukemia, Mixed Lineage Leukemia Gene Mutation | Phase 1 | Recruiting | Kura Oncology, Inc. | 420 | 2023-07-18 | 2026-03-13 |
| Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers Cladribine, Cytarabine, Dexrazoxane Hydrochloride - Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 100 | 2018-09-19 | 2026-05-22 |
| Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation Anti-thymocyte globulin (rabbit), Blinatumomab, Cyclophosphamide - Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML) | Phase 2 | Active not recruiting | St. Jude Children's Research Hospital | 170 | 2016-07-14 | 2025-08-12 |
| Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia Cytarabine, Vosaroxin - Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Completed | Vanderbilt-Ingram Cancer Center | 42 | 2016-03-01 | 2025-04-15 |
| Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation Cyclophosphamide, Fludarabine, G-CSF - Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML) | Phase 2 | Terminated | St. Jude Children's Research Hospital | 12 | 2014-10-01 | 2017-05-30 |
| Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Asparaginase, Bortezomib, Cytarabine - Acute Myeloid Leukemia, Leukemia Cutis | Phase 3 | Completed | National Cancer Institute (NCI) | 1645 | 2011-07-06 | 2026-06-02 |
Leukemia, Myeloid, Acute (8) · Sarcoma, Myeloid (8) · Hematologic Neoplasms (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Leukemia, Myelomonocytic, Juvenile (2) · Lymphoma, Non-Hodgkin (2) · Myelodysplastic Syndromes (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Anemia, Refractory, with Excess of Blasts (1) · Blast Crisis (1) · Leukemia (1) · Leukemia, Myelomonocytic, Chronic (1) · Myeloproliferative Disorders (1)
Hematologic Diseases (8) · Hemic and Lymphatic Diseases (8) · Leukemia, Myeloid (8) · Neoplasms (8) · Neoplasms by Histologic Type (8) · Neoplasms, Connective and Soft Tissue (8) · Sarcoma (8) · Leukemia (7) · Bone Marrow Diseases (4) · Chronic Disease (4) · Disease Attributes (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Myelodysplastic-Myeloproliferative Diseases (3) · Immune System Diseases (2)
Cytarabine (4) · Cyclophosphamide (2) · Daunorubicin (2) · Filgrastim (2) · Granulocyte Colony-Stimulating Factor (2) · Melphalan (2) · Rituximab (2) · Thiotepa (2) · fludarabine (2) · fludarabine phosphate (2) · Antilymphocyte Serum (1) · Asparaginase (1) · Azacitidine (1) · Bortezomib (1) · Cladribine (1)
St. Jude Children's Research Hospital (2) · Kura Oncology, Inc. (1) · M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1) · Ruijin Hospital (1) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (1) · Vanderbilt-Ingram Cancer Center (1)
United States (6) · China (2) · Australia (1) · Canada (1) · New Zealand (1) · Puerto Rico (1)
Brandon Triplett, MD (2) · Maro Ohanian (1) · Michael Savona, MD (1) · Richard Aplenc (1) · Sanjay Mohan, MD (1) · Xianmin Song, MD (1)
PMID 28419486, PMID 30773463, PMID 30987448, PMID 32029509, PMID 34596937, PMID 34855461, PMID 35349331, PMID 36815378, PMID 37267439, PMID 38295280, PMID 40294366, PMID 42085603, PMID 42227701
P30CA016672 (1), P30CA068485 (1), U10CA098543 (1), U10CA180886 (1)